FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB AP	PROVAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per respons	e: 0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Herberts Curt A. III (Last) (First) (Middle) C/O SANGAMO THERAPEUTICS, INC. POINT RICHMOND TECH CTR, 501 CANAL BLVD.						Sangamo Ticker or Trading Symbol Sangamo THERAPEUTICS, INC SGMO] Date of Earliest Transaction (Month/Day/Year) 07/14/2017											Relationship of Reporting Person(s) to Issuer neck all applicable) Director 10% Owner X Officer (give title below) below) Sr.VP & Chief Business Officer				wner specify cer
(Street)	OND C	A	94804		4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)									Lir	ne) <mark>X</mark> Fo	al or Joint/Group Filing (Check Applicable orm filed by One Reporting Person orm filed by More than One Reporting erson				
(City)	(S	tate)	(Zip)																		
		Tab	le I - No	n-Deriv	ative	Sec	curiti	es Ad	qui	ired, [Disp	osed	of, or	Ber	neficia	lly Ow	ned				
in the or occurry (mounty)			2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transact Code (In B)						d Seci Ben Owr	Amount of curities neficially vned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						c	Code	V	Amount		(A) or (D)	Price	Tran	Reported Fransaction(s) Instr. 3 and 4)				(111341.4)			
Common Stock					/2017					M		172		A	\$3.9	99 35,		5,517		D	
Common Stock				07/14	4/2017					S ⁽¹⁾		172	!	D	\$10)	35,34	5,345		D	
Common Stock 07/14				1/2017					S ⁽¹⁾		14,82	28	D	\$10)	20,517		D			
		Т	able II -	Derivat (e.g., p												y Owne	ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		n of		Expi	ate Exer iration D nth/Day/	ate		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price Derivati Security (Instr. 5	ve de Se Be Ov Fo Re Tra	Number erivative ecurities eneficially wned ollowing eported ansaction str. 4)	is Blly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exer	e rcisable		xpiration ate	Title		Amount or Number of Shares	er					
Stock Option (Right to	\$3.99	07/14/2017			M			172		(2)	10)/17/2020	Comr		172	\$0.00		3,474		D	

Explanation of Responses:

- 1. All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.
- 2. The shares underlying the stock option are fully vested and exercisable.

Remarks:

/s/ Florence Tam, Attorney-in-**Fact**

07/14/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.